So thankful and honored to receive this award! Parker Institute for Cancer Immunotherapy #cancerfearsPICI

👋 Meet Parker Senior Fellow: Cristina Puig Saus Puig-Saus Lab . 🔬 PICI Research: Unpack how T-cells respond to neoantigens in tumors and change after checkpoint blockade + Why some patients respond while others don't 🔗 Learn more: parkerici.org/the-latest/the…

Supporting junior investigators goes way beyond supporting a project. It creates the next generation of scientists that will find answers to unexplained problems and develop next-generation therapies. Thank you very much to the Parker Institute for your continued support!

So thrilled this is finally out! Great teamwork from the #downwardlab showing the effects of KRAS inhibition on anti-tumour immunity. Important clinical implications! Congratulations everyone 🥳 science.org/doi/10.1126/sc…

See the article just published by our new postdoc Edurne Mugarza showing the effects of KRAS inhibition on anti-tumor immunity. Congrats Edurne! Many more to come!

Congrats Gabri!! Super proud of you and excited to see where your project will take us!!

Grateful this Thanksgiving eve to share that I'll be opening my lab at Stanford Radiation Oncology in Jan ’23. Bittersweet to leave my alma mater UCLA, but can’t wait to work with & learn from colleagues Stanford Cancer Institute and Stanford Center for Cancer Cell Therapy.

Finally out! Here we describe the reactivity and clonal evolution of the neoAg-specific T cells over the course of treatment with ICB in patients with melanoma with and without clinical benefit. UCLA and PACT Pharma team effort! PACT Pharma Toni Ribas rdcu.be/c7avQ

A huge pleasure to be back after so many years and learn more about the amazing science done by all SETGyC members

Register for Identification of Tumor Reactive T Cells - SITC Targets in Cancer IO: Deep Dive Series. Wed., July 5, 2023 - Faculty: Stephen Elledge Harvard Medical School Alena Gros Vall d’Hebron Institute of Oncology (VHIO) Giacomo Oliveira Dana-Farber Puig-Saus Lab UCLA - ow.ly/2UUJ50P0C8p

Scientists at UCLA Health, supported by PICI, have developed new CAR T-cell therapy targeting cutaneous and rare melanoma subtypes. Led by Parker Senior Fellow Puig-Saus Lab, the research published in Nature Communications harnessed engineered immune cells to target TYRP1 protein. (1/2)

New study out in Nature Communications: UCLA researchers built & demonstrated the potential efficacy of a new CAR T-cell-based immunotherapy specifically designed to treat patients with cutaneous & rare subtypes of melanoma. Read about the new approach here: bit.ly/48eUPT7

Detection of Tumor-Reactive T Cells: Giacomo Oliveira, Cristina Puig Saus, & Stephen Schoenberger will address this topic in a session at the AACR IO Conference on Discovery and Innovation in Cancer Immunology (Feb 23-26, Los Angeles). bit.ly/4dPmHjF #AACRIO25 Puig-Saus Lab